Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

Inclusion Criteria:

* Patients who were diagnosed by the histologic, cytologic diagnosis of IIIB (malignant hydrothorax or hydropericardium) or IV non-small cell lung cancer
* ≥ 18 years old
* patients who have received more than one regimen of platinum-based chemotherapy; patients who have received EGFR monoclonal treatment could also be enrolled
* At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and can be measured by imaging tools
* have an interval of more than 4 weeks from the last chemo- or radio-therapy; 2 weeks from the last targeted therapy
* ECOG 0-2
* Expected life time longer than 3 months
* Normal laboratory values:

  * leucocyte≥ 4×109/L
  * neutrophil≥ 1.5×109/L
  * platelet≥90×109/L
  * Hemoglobin≥ 9g/L
  * ALT and AST ≤3×ULN (≤5×ULN if liver metastasis)
  * serum creatinine\<1.5 mg/dl
  * bilirubin \<1.5×ULN
* No allergy to biological drug
* Sign the consent forms

Exclusion Criteria:

* Patients who have previously received Docetaxel or anti-VEGF inhibitors
* Severe symptomatic heart disease
* Female patients during their pregnant and lactation period, or patients without contraception
* Severe uncontrolled infection
* Uncontrolled neurologic or psychiatric disease; Uncontrolled primary or metastatic brain tumor
* Patients with other malignant tumor,except for basal cell carcinoma,squamous cell carcinoma and carcinoma in situ
* Patients have accepted other clinical trials